1 |
Visilizumab |
Visilizumab |
1件: D06314 D06314 💬 |
CD3D 3件: CD3D, CD3E, CD3G 💬 |
Chagas disease 11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
096 2件: 96, 97 💬 |
2 |
Visilizumab (hum291 |
Visilizumab |
1件: D06314 D06314 💬 |
CD3D 3件: CD3D, CD3E, CD3G 💬 |
Chagas disease 11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
097 1件: 97 💬 |
3 |
Visilizumab (nuvion) |
Visilizumab |
1件: D06314 D06314 💬 |
CD3D 3件: CD3D, CD3E, CD3G 💬 |
Chagas disease 11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
097 1件: 97 💬 |
4 |
Visilizumab (nuvion® |
Visilizumab |
1件: D06314 D06314 💬 |
CD3D 3件: CD3D, CD3E, CD3G 💬 |
Chagas disease 11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
097 1件: 97 💬 |